Opinion|Videos|April 7, 2025
Clinical Considerations for Choosing a Systemic Agent for Patients With Atopic Dermatitis
Panelists discuss how standard first-line treatments for nonresponsive patients often include systemic therapies like corticosteroids or immunomodulators. Second-line options may involve biologics or advanced systemic agents. Patient input is crucial in tailoring treatments to preferences, needs, and risks.
Advertisement
Episodes in this series
Video content above in prompted by the following:
- Do you have standard first-line and second-line treatment recommendations for patients that are nonresponsive to topical treatments? How important is patient input in choosing a treatment method?
Advertisement
Related to this article
Experts outline when to stop cycling topical steroids in chronic hand eczema and where topical delgocitinib now fits.
Dupilumab cut new or worsening allergies by 34% vs placebo in a 12-trial atopic dermatitis meta-analysis, suggesting it may slow the atopic march.
Emma Guttman-Yassky, MD, discusses biomarker data showing rezpegaldesleukin's regulatory T-cell mechanism separates from placebo early.
Approval of obinutuzumab for adults with PMN follows MAJESTY, where 37% vs 6% achieved complete remission at week 104 vs tacrolimus.
A post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.
Oral icotrokinra beat placebo and was noninferior to ustekinumab in moderate to severe plaque psoriasis in the phase 3 ICONIC-ASCEND trial.
HIBISCUS showed a 48.7% vs 7.2% hemoglobin response at week 24, with an FDA decision expected in 2027.
TRANSCEND-T2D-2 topline data show retatrutide lowered A1C more and produced over twice the weight loss of semaglutide 2 mg in type 2 diabetes.
Advertisement
Advertisement
Trending on HCPLive
1
Q&A: Mucus Plugging, Multimorbidity, and GOLD 2027, With Gerard Criner, MD
2
ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema
3
Etavopivat Submitted to FDA After 27% VOC Reduction in Phase 3 SCD Trial
4
Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU Control
5